Improving AML Patient Care

AML accounts for approximately 1% of all new cancer cases and 2% of cancer-related deaths. Although the disease can affect both children and adults, incidence rates are higher in adults, especially elderly. Despite the promising wave of innovation in AML coming through, prognosis remains poor for newly diagnosed AML patients, with a 5-year relative overall survival rate of 17%.

 In addition to the life-changing impact on patients, their families and caregivers, the disease presents a significant economic burden for healthcare systems due to the very high costs when patients are hospitalised and treatment through stem cell transplantation, with these costs multiplied four-fold for patients with a more aggressive type of AML. Innovation in medicines and transplant procedures, along with care now being available at home without long hospital stays hold the potential of reducing costs, however, of equal importance is the need to reduce the significant financial, emotional and practical, everyday burden the disease places on patients, families and carers. 

This Financial Times Digital Dialogue, held in partnership with Daiichi Sankyo Europe, brought together AML patient advocates and carers, physicians, health system representatives and other leading AML experts to discuss what needs to be done to improve patient care in AML, and the actions that can be taken to reduce the economic burden of the disease while improving outcomes for patients, families and caregivers. 

This Financial Times webinar has been funded by and developed in partnership with Daiichi Sankyo, a pharmaceutical company specialising in oncology and speciality medicines. 

Experience

What is the experience and unmet needs of AML patients, families and carers, and the challenges they are facing? What is their view of how their diagnosis, treatment, care and support could be improved?

Cost

What are the cost drivers of AML treatment and care, and how might new drugs, diagnostics, new care delivery and other advances help reduce the cost burden, and improve outcomes for patients?

Patient care

What needs to be done to improve the care of patients for AML? How could an improved support system for patients, families and carers contribute to lower costs through reduced emergency care and hospitalisation, and result in better outcomes for patients and their support network?

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice